Psoriatic arthritis

      RT @AurelieRheumo: CorEvitas PsA Registry (1000+ pts)

      Analysis of biologics prescription according to disease domains

      Aurelie Najm AurelieRheumo

      3 years 4 months ago
      CorEvitas PsA Registry (1000+ pts) Analysis of biologics prescription according to disease domains No real surprise to see that IL-17i were prescribed more frequently in pts w/ PsO BSA>10% at BL Overall first line TNFi 40% > IL-17i 14% POS0309 @RheumNow #EULAR2022 https://t.co/dkLxl8d6ug
      RT @synovialjoints: The two forms of Axial PsA - classical (Axial SpA like) and alternative. Plenary session today #EULA

      Dr. Antoni Chan synovialjoints

      3 years 4 months ago
      The two forms of Axial PsA - classical (Axial SpA like) and alternative. Plenary session today #EULAR2022 by Prof. Philip Helliwell. I will be discussing this further in my vlog @RheumNow https://t.co/hxAhgMhHlJ
      RT @RichardPAConway: Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work product

      Richard Conway RichardPAConway

      3 years 4 months ago
      Kristensen et al. IL23i Risankizumab improves fatigue, health related quality of life, work productivity in PsA. @RheumNow #EULAR2022 POS1042 https://t.co/fnoCZCpwNM
      RT @RichardPAConway: Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important

      Richard Conway RichardPAConway

      3 years 4 months ago
      Nash @drpnash et al. IL23i guselkumab improves pain in PsA. Good to see as it is a really important PRO, but there is still significant work to do, week 24 - 60% had <50% and 37% had <20% improvement in pain @RheumNow #EULAR2022 POS1044 https://t.co/H92r4leslT
      RT @RichardPAConway: Mulder et al. COMPLETE-PsA trial. MTX+LEF vs MTX mono. 78 patient RCT. LEF 20mg, MTX 25mg. MTX+LEF

      Richard Conway RichardPAConway

      3 years 4 months ago
      Mulder et al. COMPLETE-PsA trial. MTX+LEF vs MTX mono. 78 patient RCT. LEF 20mg, MTX 25mg. MTX+LEF more effective (MDA 59% vs 32%) but less well tolerated (3 SAE vs 0; N+V, diarrhoea. No mention of LFTs). @RheumNow #EULAR2022 POS0078 https://t.co/2D84EFmabc
      RT @drdavidliew: So what diet to follow with autoimmunity in mind?
      So many, all with different instructions.

      Let’s co

      David Liew drdavidliew

      3 years 4 months ago
      So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ
      RT @RichardPAConway: Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improve

      Richard Conway RichardPAConway

      3 years 4 months ago
      Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improves BASDAI, mBASDAI, spinal pain, ASDAS to week 100. Still trying to get my head around this seeming to work for PsA spinal disease but not axSpA @RheumNow #EULAR2022 POS1037 https://t.co/LZgXEl6Ohl
      EULAR,poster
      EULAR 2022 – Day 3 Report
      3 years 4 months ago
      By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
      EULAR 2022 - Day 3 Faculty Panel Recap
      3 years 4 months ago
      RT @drdavidliew: Does diet drive IL-23 in IBD and PsA? Perhaps if you have the right baseline risk. The science is evolv

      David Liew drdavidliew

      3 years 4 months ago
      Does diet drive IL-23 in IBD and PsA? Perhaps if you have the right baseline risk. The science is evolving quickly Stronger rationale that diet may be really important in some patients #EULAR2022 #IL23 @RheumNow https://t.co/hV54PvfOXV
      RT @drdavidliew: Incidentally looked at the FLORA study in @RheumNow Tuesday Night Rheumatology for ‘PsA All The Wayâ€

      David Liew drdavidliew

      3 years 4 months ago
      Incidentally looked at the FLORA study in @RheumNow Tuesday Night Rheumatology for ‘PsA All The Way’, a month before #EULAR2022 https://t.co/s5qa4breCf https://t.co/a52myvJMMc
      Axial PsA vs. Axial SpA
      3 years 4 months ago
      Deucravacitinib at EULAR 2022
      • Dr. Peter Nash
      3 years 4 months ago
      RT @RichardPAConway: Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IM

      Richard Conway RichardPAConway

      3 years 4 months ago
      Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk @RheumNow #EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
      RT @uptoTate: LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC&gt;3, SJC&gt;5, CRP&g

      Dr. Rachel Tate uptoTate

      3 years 4 months ago
      LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, enthesitis, dactylitis, BMI>30  & sDMARDs tx constitutes negative predictive impact on MDA/LDA after 1 yr. #EULAR2022 POS0080 @RheumNow https://t.co/PugwiuSMPm https://t.co/nqadEjA3Xe

      Catch up on Conference Podcasts

      ×